Welcome to Trendlines
We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >
Subscribe to Our Newsletter
Stay in Touch
Editor’s note: IonMed was featured in Israel21C on November 16, 2015
By: Abigail Klein Leichman
One year after receiving CE clearance in Europe for its Bioweld1 cold-plasma system for closing surgical incisions, Israel’s IonMed has completed clinical trials in Queen Astrid Military Hospital in Brussels — the largest burn center in Europe – showing the system’s advantages in skin-graft fixation over sutures, fibrin glue or staples.
“Staples account for about 90-plus percent of the market. Fibrin glue is very expensive so although it’s good, many hospitals and clinics cannot afford to use it,” explains IonMed clinical manager Dr. Yaara Yarmut. “Staples create local pressure points that can lead to necrosis or infection. The advantage of our device is that it is cheaper than fibrin glue and more efficient than staples.”
The startup, based in the Lower Galilee city of Yokneam Ilit, will next focus on the treatment of skin diseases including acne. Yarmut said cold plasma has characteristics that can change the mechanisms involved in the formation of acne lesions. “We’re working on performing a clinical trial in Europe for this application,” she says.
IonMed CEO Shai Levanon says cold plasma “holds enormous promise as a new therapeutic paradigm in wound care, and more broadly in medicine.”
In addition to sealing wounds, cold plasma speeds healing and has antimicrobial properties.
Until now, the company has been supported by its major shareholders, The Trendlines Group and Generali Financial Holdings Fund.
“However, to make progress in commercialization, especially after our success in the skin-graft trial, we are looking for additional investors to join us,” says IonMed CEO Shai Levanon.